Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis
A live, multi-source view of Harmony Biosciences Holdings, Inc. (HRMY): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome.
Sector: Healthcare · Industry: Biotechnology · United States · 293 employees · harmonybiosciences.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Harmony Biosciences Holdings, Inc. (HRMY) had a market capitalization of $2.46B, a trailing P/E of 13.7 (forward 6.3) and a beta of 0.93; the shares traded in a 52-week range of $25.52 – $43.49 (17.9% over the year).
- Market cap
- $2.46B
- Enterprise value
- $1.95B
- Trailing P/E
- 13.7
- Forward P/E
- 6.3
- Price / book
- 2.46
- EPS (trailing)
- $3.09
- EPS (forward)
- $6.69
- Payout ratio
- 0.0%
- 52-week range
- $25.52 – $43.49
- 52-week change
- 17.9%
- Beta
- 0.93
- Average volume
- 816,607
- Shares outstanding
- 58.2M
- Short % of float
- 9.49%
- Profit margin
- 18.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Harmony Biosciences Holdings, Inc. (HRMY) last closed at $42.25 (the last completed close before that scan).
Technicals at the scan: RSI 66 (neutral territory), price +6.7% versus its 20-day average, 20-day versus 50-day average spread +5.4%, MACD histogram 0.25.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 66/100.
Next scheduled company event: in 56 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for HRMY in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
HRMY has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Harmony Biosciences Holdings, Inc. (HRMY) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell HRMY.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.